Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

Peter Y. F. Zeng,1,2 Matthew J. Cecchini,2 John W. Barrett,3 Matthew Shammash-Toma,4 Lois De Cecco,5 Mara S. Serafini,6 Stefano Cavalli,6,7 Lisa Licita,8,9 Frank Hoebers,10 Ruud H. Brakenhoff,11 C. René Lemans,12 Kathrin Schechenbach,13 Tito Poli,14 Xiaowei Wang,15 Xinyi Liu,14 Francisco Laxague,16 Etian Prisman,17 Catherine Poli,18,19 Pinaki Bose,20 Joseph C. Dort,21 Mushfiq H. Shaikh,22 Sarah E. B. Ryan,23 Alice Dawson,24 Mohammed I. Khan,25 Christopher J. Howlett,26 William Stecha,27 Paul Plantinga,28 Sabrina Daniela da Silva,29 Michael Hier,30 Halsea Khan,31 Danielle MacNeil,32,33 Adrian Mendoza,32,34 John Yoo,32,35 Kevin Fung,32,35 Pencilla Lang,32,35 Eric Winquist,32,35 David A. Palma,32,35 Hedyeh Ziai,32,35 Antonio L. Amelio,36 Shawn S-C. Li,37 Paul C. Boutros,38,39,40 Joe S. Mymryk,38,39,40 and Anthony C. Nichols3

1Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada
2Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada
3Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
4Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
5Department of Radiation Oncology (MAASTRO), Research Institute GROW, Maastricht University, Maastricht, the Netherlands
6Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands
7Department of Otolaryngology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
8Unit of Maxillofacial Surgery, Department of Medicine and Surgery, University of Parma—University Hospital of Parma, Parma, Italy
9Department of Pharmacology and Regenerative Medicine, The University of Illinois at Chicago, Chicago, IL, USA
10Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada
11Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada
12Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
13Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada
14Department of Otolaryngology Head and Neck Surgery, McGill University, Montreal, Quebec, Canada
15Department of Oncology, University of Western Ontario, London, Ontario, Canada
16Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada
17Lineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
18Department of Cell Biology and Physiology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
19Department of Biochemistry, University of Western Ontario, London, Ontario, Canada
20Department of Human Genetics, University of California, Los Angeles, CA, USA
21Department of Urology, University of California, Los Angeles, CA, USA
22Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA
23Institute for Precision Health, University of California, Los Angeles, CA, USA
24Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, CA, USA
25Department of Microbiology & Immunology, University of Western Ontario, London, Ontario, Canada

Summary

Background There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the generally favourable prognosis. However, 15–30% of patients recur after primary treatment, reflecting a need for improved risk-stratification tools. We sought to develop a molecular test to risk stratify HPV+ OPSCC patients.

*Corresponding author. Department of Otolaryngology - Head and Neck Surgery, Victoria Hospital, London Health Science Centre, Room B3-433A, 800 Commissioners Road East, London, ON, Canada N6A 5W9.

E-mail address: anthony.nichols@lhsc.on.ca (A.C. Nichols).

These authors contributed equally to this paper.

This study was funded by a Canadian Institutes for Health Research (CIHR) grants MOP 340674 to ACN and PCB and PJT-173496 to JSM and ACN. PCB was supported by was supported by the NIH/NCI under award number P30CA016042. LDC was supported by European Union Horizon 2020 Framework Program Award Number: 689715 and AIRC ID 23573. ACN was supported by the Wolfe Surgical Research Professorship in the Biology of Head and Neck Cancers Fund.

104373
Published online xxx https://doi.org/10.1016/j.ebiom.2022.104373
Methods We created an immune score (UWO3) associated with survival outcomes in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes.

Findings A three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival compared to the immune desert (HR = 9.0, 95% CI: 3.2–25.5, \(P = 3.6 \times 10^{-5}\)) and mixed (HR = 6.4, 95% CI: 2.2–18.7, \(P = 0.006\)) groups after adjusting for age, sex, smoking status, and AJCC8 clinical stage. Finally, UWO3 was able to identify patients from two small treatment de-escalation cohorts who remain disease-free after aggressive de-escalation to 30 Gy radiation.

Interpretation With additional prospective validation, the UWO3 score could enable biomarker-driven clinical decision-making for patients with HPV+ OPSCC based on robust outcome prediction across six independent cohorts. Prospective de-escalation and intensification clinical trials are currently being planned.

Funding CIHR, European Union, and the NIH.

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Head and neck squamous cell carcinoma; Transcriptomics; Biomarkers; Cancer immunology; HPV; De-escalation

Research in context

Evidence before this study HPV-associated oropharyngeal cancer (OPSCC) is one of the fastest rising cancers in North America. While cure rates can be high, up to 30% of patients recur after primary treatment. Current multimodal treatment regimens are historically derived from clinical trials for the more aggressive HPV-negative OPSCC and may be more intensive than necessary for most HPV+ OPSCC patients. Thus, there is significant interest in treatment de-intensification for HPV+ OPSCC.

Added value of this study We defined three clinically-translatable and biologically-plausible immune classes in HPV-associated OPSCC using a three-gene expression score. Our three gene-expression score was associated with distinct disease-free survival and overall survival in five independent cohorts which included 863 patients. More importantly, the three-gene expression score was associated with recurrence status following aggressive radiation de-escalation.

Implications of all the available evidence The UWO3 immune score may identify patients with improved prognosis. Further studies in the context of a randomized trial will be needed to confirm these results.

Introduction The incidence of human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is increasing worldwide.1 HPV+ OPSCC is biologically and clinically distinct from non-HPV-driven (HPV−) HNSCC, which is typically associated with tobacco and alcohol consumption.2–5 Although HPV+ OPSCC patients are usually younger and exhibit markedly improved outcomes compared to HPV− OPSCC patients,1 current treatment guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend identical treatment regimens of high-dose cisplatin and 70 Gy radiation (CRT) independent of HPV status.6,7 The rising incidence of HPV+ OPSCC is leading to an increasing number of young survivors, making post-treatment quality of life and treatment-related morbidities a major concern. There is significant interest in treatment de-intensification for HPV+ OPSCC patients to reduce morbidity rates, while maintaining excellent cure rates.8–17
Treatment de-intensification efforts have been complicated by the ~15–30% recurrence or metastasis rate of HPV+ OPSCC patients treated with the current standard of care therapy. Early efforts at de-intensification demonstrated that modification of current standard of care CRT can result in harm for patients. Both the De-ESCALaTE HPV and RTOG1016 phase III randomized trials found that substitution of cetuximab for cisplatin led to inferior survival outcomes. Reflecting these unsuccessful attempts that led to poorer outcomes for patients on the experimental arm, recent treatment de-intensification guidelines from ASCO29 and the Head and Neck Cancer International Group30 have called for de-intensification to only be attempted in the context of a clinical trial for patients with favorable risk profiles. Thus, the ideal treatment de-intensification method and patient population remain highly controversial.30–36

Molecular biomarkers reflecting the biology of the tumour may better risk-identify patients who are ideal candidates for treatment de-intensification. HPV+ head and neck cancer treatment failure has been linked to TP53 mutations,27 tumour hypoxia,28 keratinocyte differentiation,29 metabolism,30 chromosome 3p arm loss,31 and HPV-related transcriptional programs.32 These findings have not yet been thoroughly validated, require complex assays only available at select institutions, or generally exhibit modest effect-sizes that explain only a fraction of HPV+ head and neck cancer treatment failures. There remains an urgent need for improved risk-stratification to guide therapeutic decision-making in balancing treatment toxicity and therapeutic efficacy.

We created a clinically translatable immune classification tool strongly associated with survival outcomes in HPV+ OPSCC based upon the abundance of three transcripts. We validated it in five HPV+ OPSCC cohorts comprising 863 patients, including two blinded cohorts and a tissue microarray (TMA) cohort using immunohistochemistry. Finally, we show this immune classification to only be attempted in the context of a clinical trial for patients with favorable risk profiles. Thus, the ideal treatment de-intensification method and patient population remain highly controversial.30–36

**Methods**

**Ethics**

The study was approved by the Research Ethics Boards at Western University (REB 7182) and informed consent was obtained from each patient.

**Patient cohort**

Primary site fresh tumour samples were prospectively collected from patients with HPV+ OPSCC at Victoria Hospital, London Health Science Centre, London, Ontario, Canada between 2010 and 2016. Patient demographics and survival outcomes were prospectively collected. Frozen section analysis was carried out to confirm tumour cellularity greater than 70%. HPV status was confirmed via p16 immunohistochemistry, as well as polymerase–chain reaction and Sanger sequencing. Detailed clinical information in the LHSC cohort is provided in Supplementary Table S1. There were no other exclusion criteria. Disease free survival was defined as time from diagnosis to recurrence at any site or death. Recurrence was defined as the presence of local, regional, or distant disease after completion of treatment. The Cancer Genome Atlas (TCGA, n = 71),35 Johns Hopkins University (JHU; n = 47), BD2Decide (n = 286), and Washington University (WashU) and Vanderbilt University (n = 262) cohorts are public HPV+ OPSCC transcriptomic cohorts and have been described elsewhere.36–40 Detailed descriptions of all other cohorts have been provided elsewhere.36–40 Treatments received for each cohort are described in Supplementary Table S2. All cohorts except for the TCGA cohort are HPV+ tumours solely from the oropharynx region. The only cohort that contained tumours from the non-opharynx region is that of the TCGA, which is 75% oropharynx. The reporting of the study followed guidelines from Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK)41 and STROBE.42

**RNA processing and sequencing**

Total RNA and DNA was isolated using Qiagen AllPrep DNA/RNA kits. HPV status was confirmed by real time PCR as we have previously described.43–44 One microgram of total RNA was shipped to The Center for Applied Genomics (Hospital for Sick Children, Toronto, ON) for quality control, library preparation, and sequencing. RNA quality was confirmed with a Bioanalyzer and libraries were prepared using a NEB Ultra II Directional mRNA library kit. Samples were then processed using random primers and paired end sequencing using an Illumina HiSeq 2500 yielded 50–90 million reads/sample (median: 66 million reads, Supplementary Table S1).

FASTQ files were pre-processed with trim_galore (v0.6.4) and then quality controlled using FastQC (v0.11.9). Each sample was mapped to the human reference genome GRCh38 (v97) using STAR aligner (v2.7.2b) in two-pass mode,45 and quantified using HTSeq-count (v0.12.3) intersection-strict mode.46 Read normalization and differentially expressed gene testing were conducted using DESeq2 (v1.26.0).47 Differentially abundant transcripts between the disease-free and recurrent patients were defined as transcripts having at least an average of normalized reads of 10, an absolute log2 fold change (log2FC) greater than 2, and a Benjamini-Hochberg adjusted P-value of less than 0.05. Generation and processing of external cohorts have been described elsewhere.36–40

www.thelancet.com Vol 86 December, 2022 3
HPV genotyping via HPV transcript quantification

HPV genotyping was performed on raw RNA-seq reads using HPViewer (branch c62f29e, available at https://github.com/yuhanH/HPViewer), on a database of 182 repeat masked HPV strains. HPV reads were then quantified using HTSeq-count intersection-strict mode to the subtype with the highest read-number.48

Tumour microenvironment estimation

The tumour microenvironment (TME) composition of each sample was estimated using the MCP-counter score (v1.1.0).49 The score was based on previously analyzed transcriptomic markers that were found to be characteristic of the specific immune population and were proportional to the abundance of each cell population within the tumour. Comparisons with other immune deconvolution methods have found the method to be highly accurate and capable of inter-sample comparisons.49 The MCP-counter signatures composition are as follows: T cells: CD28, CD3D, CD3G, CD5, CD6, CHRM3-AS2, CTLA4, FLT3LG, ICOS, MAL, PBX4, SIRPG, THEMIS, TNFRSF25, and TRAT1; B lineage: BANK1, CD19, CD22, CD79A, CR2, FCRL2, IGKC, MS4A1 and PAX5; natural killer cells: CD160, IRF4, PD1, TRAIL; myeloid dendritic cells: CD1A, CD1B, CD1E, ADAP2, CSF1R, FPR3, KYNU, PLA2G7, RASSF4, and NCR1, PTGER4, and SH2D1B; monocytic lineage: CAPG, CEBPA, CEBPB, CD14, CD16, CLEC10A, CLEC2, and CD163; neutrophils: CA4, TFEC; myeloid cells: CD1A, CD1B, CD1E, ADAP2, CSF1R, FPR3, KYNU, PLA2G7, RASSF4, and NCR1, PTGER4, and SH2D1B; monocytic lineage: ADAP2, CSF1R, FPR3, KYNU, PLA2G7, RASSF4, and TFEC; myeloid dendritic cells: CD1A, CD1B, CD1E, CLEC10A, CLEC2, and WDFC21P; neutrophils: CA4, CEACAM3, CXCR1, CXCR2, CYP4F3, FCGR3B, HAL, KCNJ15, MEGF9, SLC25A37, STEAP4, TECPR2, TLE3, TNFRSF10C, and VNN3; endothelial cells: ACVR1L, APLN, BCHE, BMP6, BMX, CDH5, CLEC14A, CXorf36 (also known as DIPK2B), EDN1, ELTDL1, EMCN, ESAM, ESM1, FAM124B, HECW2, HHIP, KDR, MMRN1, MMRN2, MYCT1, PALMD, PEAR1, PGF, PLXNA2, PTPRB, ROBO4, SDPR, SHANK3, SHE, TEC, TIE1, VEPH1, and VWF.

Clustering

K-means clustering was performed on Z-scores of the immune cell abundance estimation (Supplementary Figure S1a) using the kmeans wrapper of ComplexHeatmap package (v2.1.0) when generating heatmaps.49 Kmeans was run 1000 times to generate consensus k-means clustering. The number of K clusters was selected using the silhouette method through the fviz_nbclust function of the factoextra R package (v1.0.6).

Immune gene signatures

Immune gene signatures were derived from other studies.50 Each signature was computed as the geometric mean of the abundance of its included genes: immunosuppression (TGFBI, TGFBI1, LGALS1 and CXCL12), regulatory T cells (FOXP3 and TNFRSF18), T cell survival score (CD70 and CD27), T cell activation (CXCL9, CXCL10, CXCL16, IL15, and IFNG), myeloid chemotaxis (CCL2), MHC I (HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G and B2M), and tertiary lymphoid structures (CXCL13).

UWO3 score development and prediction

Statistically significant transcripts between disease-free and recurrent tumours were filtered to only include transcripts whose abundance was independently associated with prognosis. The cohort was dichotomized into high and low abundance groups for each transcript and tested for association with prognosis in a Cox proportional hazard multivariate model including important clinical variables (age at diagnosis, sex, T stage, N stage, smoking status, alcohol abuse status). The abundance of transcripts with an FDR <0.25 were normalized using DESeq2, log-10 transformed, and Z-score standardized for score development. To facilitate the development of protein diagnostic tools for pathology, the gene lists were further filtered to contain genes for which the RNA abundance was highly correlated with its protein abundance (FDR <0.05 & rho >0.6, Spearman Correlation) using the HPV-negative HNSCC CPTAC cohort.51

For the development of the UWO3 score to differentiate between the 3 TME immune classes (immunoreactive, mixed, and immune desert), we used a regularized linear regression technique based on the LASSO algorithm, as implemented in the glmnet (v3.0-2) R package using 5-fold cross-validation. The score was trained with a “Gaussian” family model to minimize mean squared error (MSE). A minimal subset of 3 genes (CD3E, IRF4, and ZAP70) was outputted by LASSO, that we labeled the UWO3 score. The UWO3 score can be calculated with the following equation: $UWO3 = 2.232 - 0.224 + IRF4 \times 0.137 + CD3E \times 0.273$. Cutoffs were determined by maximizing the correct number of tumours assigned to the same immune subtype through clustering using the cutpointr package (v1.1.0) to find all acceptable cutpoints within a range of 0.01 by setting the toI_metric = 0.01. Using UWO3, tumours were then assigned to an immune class as follow: $UWO3 \leq 2$ were predicted be “immunoreactive”, $2 < UWO3 \leq 2.5$ were predicted to be “mixed”, and $UWO3 > 2.5$ were predicted to be “immune desert”. An online UWO3 calculator is available (https://www.nicholslab.com/uwo3calculator).

Tissue microarray and immunohistochemistry

All samples were obtained with informed consent after approval of the Institutional Review Board at Western University, the University of Calgary, and the University of British Columbia. The TMAs from University of British Columbia have been approved of the Institutional Review Board at Western University, the University of Calgary, and the University of British Columbia. The TMAs from University of British Columbia have been
The TMA from Western University were processed as following: The formalin-fixed paraffin-embedded (FFPE) blocks for each tumour were sectioned and stained with hematoxylin & eosin (H&E) to confirm the presence of tumour tissue. A Manual Tissue Arrayer (MTA-1; Beecher Instruments Inc.) was used to punch out 3-4 cylindrical cores of 0.6 mm diameter from each tumour sample. Cores were arrayed into recipient paraffin blocks. Control tissues were also included on each block. Cores were sealed into recipient blocks by heating at 40 °C for ~40mins. Blocks were sectioned into 1.5 μm sections and affixed to glass slides. Every ninth slide was stained with H&E to provide a reference. Additional details are available in the MTA-1 Instruction Manual (<www.beecherinstruments.com>). IHC staining was completed at the Department of Pathology & Laboratory Medicine and the Molecular Pathology Core Facility (Western University). Tissues were examined using an Aperio ScanScope® slide scanner and staining quantification was performed using QuPath (v0.2.3).

To translate the UWO3 score for use in TMAs, we stained the TMA with anti-CD3 (IR503, Agilent Dako), anti-ZAP70 (clone 2F3.2, IR653, Agilent Dako), and anti-IRF4 (clone MUM1p, IR644, Agilent Dako) antibodies on an Omnis staining platform (Agilent Dako). The tumour was contoured by a subspecialist pathologist and the number of cells within the tumour positive for each marker was quantified using the positive cell detection function in QuPath. The percentage of positive cells within each tumour was then used to create Z-scores and to calculate the UWO3 score using the same equation as RNA-based assays. Using UWO3, tumours were then assigned to an immune class as follow: UWO3 ≤ 2 were predicted to be “immune rich”, 2 < UWO3 ≤ 2.5 were predicted to be “mixed”, and UWO3 > 2.5 were predicted to be “immune desert”.

**Role of funders**

The funding sources had no roles in the design of the study, the collection, analysis, and interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.

**Results**

**Development and validation of the UWO3 immune classification**

To reveal transcriptomic features predictive of treatment response, we performed RNA-seq on 43 HPV+ OPSCC tumours, 16 of which experienced local, regional, or distant recurrence. As specific TME alterations are associated with recurrence in HPV+ OPSCC, we characterized the TME by the abundance of distinct cell populations. Through unsupervised clustering of these estimated immune cell abundances (see Methods), we classified samples into three categories: “immune rich”, “immune desert”, and “mixed” (Supplementary Figure S1a). These three TME subtypes exhibited distinct patterns of overall (OS; \(P = 0.003\), log rank test; Supplementary Figure S1b) and disease-free survival (DFS; \(P < 10^{-4}\), log rank test; Supplementary Figure S1c). To facilitate translation of these results into the clinic, we developed a minimal classifier based on using the Least Absolute Shrinkage and Selection Operator (LASSO; see Methods, Supplementary Figure S2) to stratify patients into one of three immune classes. The resulting classifier, which we call University of Western Ontario 3 (UWO3), is based on the abundance of three transcripts (CD3E, IRF4 and ZAP70) and assigns immune classes strongly associated with DFS in our discovery cohort, as expected (\(P < 10^{-5}\), log rank test, Supplementary Figure S3a).

**Statistics**

All statistical analyses were performed with R software (v4.0.5) using the following packages: survival (v3.2.10), ggpubr (v0.4.0), stats (v4.0.5), and rms (v6.2-0). Wilcoxon rank sum test (2 categories) and Kruskal-Wallis test (>2 categories) were used to examine all relationships between categorical variables and quantititative variables. \(P\)-values were corrected for multiple testing using the Benjamini-Hochberg method. The Fisher’s Exact test was used to analyze contingency tables. Survival was analyzed with the log-rank test and Cox proportional hazards model with the survival (v3.1-12) package. The proportional hazards assumption was assessed using Schoenfeld residuals. Hazard ratio in the JHU cohort was estimated using Cox Regression with Firth’s penalized likelihood, implemented using the coxphf package (v1.13.1), as monotone likelihood is observed due to no events in the immune rich group. Meta-analysis of the association between UWO3 immune class and disease-free survival was performed using the inverse variance method through the R package meta (v5.1-1) using log10HR and SEM in a fixed-effect model. The significance of any discrepancies in the estimates of the treatment-effects from the different cohorts was assessed using Cochrane’s test for heterogeneity and the \(I^2\) statistic as described previously. Heterogeneity was considered statistically significant if the \(P\) value was less than 0.10 for the \(\chi^2\) test. Brier’s error analysis of Cox models was calculated using the package pec (v2021.10.11). The predictive accuracy of UWO3 score was evaluated by the c-index with 1000 × bootstrap resampling, as described previously. The relative importance of each parameter to survival risk was assessed using the \(\chi^2\) from R package rms (v6.2-0). All tests were 2-sided.
We next tested five independent cohorts to validate the association between UWO3 immune class and survival outcomes in HPV+ OPSCC. We first used The Cancer Genome Atlas (TCGA; n = 71) and Johns Hopkins University (JHU; n = 47) HPV+ OPSCC RNA-seq cohorts. In both, the immune rich patients had improved DFS and OS (TCGA: P = 0.01, JHU: P = 0.02, log rank test, Fig. 1a, c, Supplementary Figure S3b, c).

Next, we employed clinically-validated antibodies for the proteins corresponding to the transcripts within the UWO3 score (CD3E, ZAP70 and IRF4) that are used routinely in clinical pathology labs for hematologic malignancies. As immunohistochemistry (IHC) is cost-effective and broadly available, we applied the UWO3 score to a TMA consisting of 197 independent HPV+ OPSCC patients treated uniformly with radiation (70 Gy) with concurrent cisplatin (Supplementary Figure S4a). Immune desert patients experienced inferior DFS (HR = 3.1, 95% CI 1.1–9.7, P = 0.038, univariate Cox model; Fig. 1a, Supplementary Figure S4b) compared to the immune rich patients, highlighting the potential of the UWO3 immune classification to be implemented as an IHC assay.

Finally, to validate the association between UWO3 score and survival outcomes, we performed blinded validations in a retrospective cohort and a prospective cohort. Patients were assigned to immune classes using UWO3 before unmasking of clinical outcomes. In a retrospective cohort of HPV+ OPSCC patients (n = 262) profiled using RNA-seq of FFPE samples treated primarily with surgery at WashU at St Louis and Vanderbilt University, the immune classes exhibited distinct DFS (P = 0.01, log rank test; immune desert vs. immune rich: HR = 2.5, 95% CI 1.3–4.7, P = 0.004, univariate Cox model; Fig. 1a, c, Supplementary Figure S5a) and OS (P = 0.01, log rank test; immune desert vs. immune rich: HR = 3.44, 95% CI 1.59–7.44, P = 0.002, univariate Cox model; Fig. 1b, d, Supplementary Figure S5a). In the prospective Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide) study (n = 286, NCT02832102) of 286 locoregionally-advanced p16-positive patients profiled using RNA-microarray and treated with radiation with or without chemotherapy at seven European institutions, the immune classes exhibited distinct DFS (P = 0.03, log rank test; immune desert vs. immune rich: HR = 2.6, 95% CI 1.1–5.7, P = 0.02, univariate Cox model; Fig. 1a, c, Supplementary Figure S5c) and OS (P = 0.004, log rank test; immune desert vs. immune rich: HR = 5.0, 95% CI 1.6–15, P = 0.004, univariate Cox model; Fig. 1b, d, Supplementary Figure S5d). Taken together, we have shown that the UWO3 immune class is robustly associated with survival outcomes in six independent cohorts across different profiling platforms and geographic jurisdictions.

Pooled analysis of all cohorts demonstrates that UWO3 immune class is a strong independent predictor of survival

As the association between immune groups and survival outcomes for each cohort were homogeneous between cohorts (P2 < 0.05, P > 0.10; Fig. 1a–d), we performed a pooled analysis of all five validation cohorts (TCGA, JHU, TMA, WashU, and Vanderbilt) and BD2Decide; total n = 863), excluding the LHSC discovery cohort. The immune class defined by UWO3 was strongly associated with DFS (P = 3 × 10−6, log rank test, Fig. 1e) and OS (P = 1 × 10−7, log rank test, Fig. 1f) in this pooled cohort.

The 5-year DFS probabilities for the immune rich, mixed, and immune deserts group were 87.8% (95% CI 83.5%–92.3%), 76.1% (95% CI 71.2%–81.4%), and 69.9% (95% CI 64.2%–76.1%), respectively. Immune desert patients exhibited inferior DFS over the immune rich (HR = 2.87, 95% CI 1.9–4.4, P = 1 × 10−4, univariate Cox model; Fig. 1e). The mixed patients also exhibited worse DFS over the immune rich patients (HR = 2.21, 95% CI 1.4–3.4, P = 3 × 10−3, univariate Cox model; Fig. 1e). The 5-year OS probabilities for the immune rich, mixed, and immune deserts group were 90.2% (95% CI 86.2%–94.4%), 80.7% (95% CI 75.8%–85.9%), and 72.8% (95% CI 67.1%–79.0%), respectively. Immune desert patients exhibited inferior OS over the immune rich (HR = 2.74, 95% CI 1.8–4.2, P = 4 × 10−4, univariate Cox model; Fig. 1f) and mixed (HR = 1.46, 95% CI 1.0–2.1, P = 0.028, Fig. 1f) patients. The patients with mixed tumours also exhibited worse OS than immune rich patients (HR = 1.87, 95% CI 1.2–2.9, P = 0.0060, univariate Cox model; Fig. 1f). The survival differences by UWO3 immune group persisted for patients undergoing both primary surgery (n = 324; Immune rich vs. immune desert DFS: HR = 3.12, 95% CI 1.7–5.9, P = 0.0004, univariate Cox model; Supplementary Figure S6a, b) or primary radiation (n = 293; immune rich vs. immune desert DFS: HR = 4.81, 95% CI 2.0–11.4, P = 0.0003, univariate Cox model; Supplementary Figure S6c, d).

In a multivariate Cox proportional hazards model stratified for cohort, the association between the UWO3 immune class and DFS was independent of other clinical factors (immune desert vs. immune rich: HR = 9.0, 95% CI 3.17–25.5, P = 3.6 × 10−6; mixed vs. immune rich: HR = 6.4 (95% CI 2.2–18.7, P = 0.0006; Table 1). Brier score analysis demonstrates that the UWO3 immune group alone had a lower prediction error for disease-free survival than a Cox model of clinical factors (AJCC8 stage, sex, smoking status, and age) (P = 0.049, χ2 test; Fig. 2a). Furthermore, integration of the UWO3 immune group with other clinical factors (UWO3 + Full Clinical) further decreased prediction error (P = 5 × 10−7, χ2 test; Fig. 2a). We analyzed the relative contribution of each parameter to predict DFS and identified the UWO3 immune group classification...
(50.9%, Fig. 2b) as the strongest parameter, compared to other clinical factors. Finally, the UWO3 score was also superior at predicting DFS compared to levels of tumour infiltrating lymphocytes (as determined by CD3E abundance) (Supplementary Figure S7). Thus, UWO3 immune class is a strong independent prognostic factor that can improve the risk-stratification of HPV+ OPSCC.
UWO3 immune classification has implications for treatment de-intensification

As the immune rich patients exhibited excellent survival outcomes, we hypothesized that the UWO3 score could identify patients who respond favourably to de-intensified treatment. We used RNA-seq data from the phase II MC1273 (NCT01932697) trial, which tested an aggressive de-escalation regimen of 30 Gy radiation with concurrent docetaxel post-surgery and the 30ROC trial (NCT00606294), in which patients received 30 Gy radiation and cisplatin. The UWO3 score was associated with higher odds of recurrence following aggressive treatment de-escalation (Odds ratio: 24.9, \( P = 0.0147 \), logistic regression with UWO3 as continuous variable stratified for cohort; Fig. 3). Strikingly, 7 out of 9 patients (77.8%, Fig. 3) in the immune desert group developed recurrence, while only 4 out of the 24 patients (16.6%) in the immune rich and mixed groups recurred. While limited by the sample size, these results support the potential ability of the UWO3 score to identify patients who will maximally benefit from aggressive treatment de-escalation.

Discussion

Although HPV+ OPSCC patients have improved prognosis over their HPV-negative counterparts, a significant portion of patients still recur after initial treatment and are at risk of death. Molecular biomarkers that reflect the unique biology of HPV+ OPSCC such as tumour hypoxia, mutation status, or immune activation may refine patient prognosis and selection for de-escalation clinical trials. In the current study, we demonstrate that the pre-treatment TME has dramatic effects in determining the prognosis of HPV+ OPSCC patients. Further, we describe a clinically translatable, extensively validated UWO3 immune classification tool that may allow biomarker-driven individualized treatment in HPV+ OPSCC (Fig. 4). The proposed immune classification reflects HPV+ OPSCC biology. CD3E is part of the T-cell receptor complex and its down-regulation on T-cells has been linked to worse prognosis in OPSCC. ZAP70 plays an important role in T-cell receptor signaling but is also highly expressed on NK-cells. IRF4 directs the development, affinity maturation, and terminal differentiation of B cells, but also plays important roles in monocyte differentiation. Accumulating evidence suggests that rich immune infiltration distinguishes...
HPV+ OPSCC from both HPV-negative OPSCC and cervical cancer, a cancer type with similar HPV-viral etiology. There could be several reasons underlying the difference in the TME specifically in HPV+ OPSCC. The oropharynx region includes the Waldeyer’s tonsillar ring of lymphoid organs that are densely infiltrated with immune cells. Furthermore, HPV+ OPSCC is virally-driven and thus expresses unique viral antigens. The presence of viral-host fusion proteins following HPV integration in some tumours may be strongly immunogenic and stimulate anti-tumour immunity. Recent work using single-cell RNA-sequencing has identified high proportions of HPV antigen-specific tumour infiltrating lymphocytes in HPV+ OPSCC, including a subset of PD1+ TIM3+ (the protein encoded by the gene HAVCR2) terminally differentiated CD8 T-cells within HPV+ OPSCC tumours that fail to proliferate following antigen stimulation. Multiple studies are ongoing to assess the relevance of TIM3 inhibition in a variety of tumour types. Further work will be needed to investigate whether the addition of immunotherapy (such as anti-PD1 and/or anti-TIM3) to CRT can stimulate anti-tumour immunity and improve survival outcomes for HPV+ OPSCC patients with an immune desert TME.

Patients with immune rich pre-treatment tumours have improved prognosis compared to the mixed and immune desert groups consistently across six different cohorts regardless of treatment. Thus, patients who are immune rich and have favorable clinical factors may be ideal candidates for aggressive treatment de-intensification. The inflammatory TME of the immune rich group and dense infiltration of PD1+ CD8 T cells pre-treatment supports further exploration of substitution of chemotherapy with immunotherapy in de-escalation settings. The three-arm phase III randomized controlled trial NRG-HN005 (NCT03952585) is currently evaluating such a regimen (60 Gy plus nivolumab) against the standard treatment of 70 Gy with cisplatin and a de-intensified regimen of 60 Gy plus cisplatin. Furthermore, the association between patients who have immune desert pre-treatment tumours and poor survival outcomes supports the investigation of neoadjuvant immunotherapy approaches, which have been found to increase T-cell density within OPSCC tumours.

The key limitation of our study is that the treatment protocols delivered in each cohort were not uniform. However, the strong association of UWO3 with DFS in six cohorts, which span different geographic jurisdictions, treatment methods, and patient populations suggests that the immune classes can treatment-agnostically predict survival outcomes. Another limitation of the current study is that the TCGA cohort contains 25% of tumours from outside of the oropharynx. Given that over 98% of the tumours used in this study (888/906) are from the oropharynx, and the HPV+ oropharyngeal patients have similar survival patterns as the TCGA cohort including both HPV+ non-oropharynx and oropharynx tumours, we believe the inclusion of data from the very small number of tumours from other subsites present within the TCGA cohort will be very unlikely to influence the interpretation of this classification system for HPV-associated OPSCC. Finally, another limitation of the current study is that cohorts were profiled using different
technologies such as RNA-seq, RNA microarray, and immunohistochemistry. However, the strong association between the UWO3 and survival outcomes despite these differences highlights the independence of the UWO3 score with respect to profiling technology and may facilitate clinical implementation. Development of a College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) approved assay is underway to further assess its analytical and clinical validity. Ultimately, validation of the UWO3 score using a CLIA-CAP approved assay within the context of a randomized controlled trial population will be required before clinical adoption.

In summary, the ideal patient population for treatment de-intensification and intensification in HPV+ OPSCC remains controversial. Upon further analytical validation, our retrospectively and prospectively-validated immune classification may provide a readily implemented means to identify patients with improved prognosis. Further prospective studies in the context of a randomized controlled trial will be needed.

**Fig. 4: UWO3 immune classification of HPV+ HNSCC has implications for treatment de-intensification and immunotherapy.** CI: confidence interval; DFS: disease-free survival; OS: overall survival.

| Immune group | Immune Rich | Mixed | Immune Desert |
|---------------|-------------|-------|---------------|
| % of patients | 32.3%       | 36.3% | 31.3%         |
| Sex           |             |       |               |
| AJCC8 stage   |             |       |               |
| Age (Years)   |             |       |               |

---

**Avenues for future research**

- Reduced radiation
- Reduced cisplatin
- Transoral robotic surgery, +/- de-escalated adjuvant radiotherapy
- Full/partial substitution of cisplatin with other systemic agent (e.g immunotherapy)

- For patients with additional unfavorable clinical factors: Chemotherapy and/or radiation intensification
- Induction chemotherapy
- Immunotherapy (e.g. anti-PD1, anti-PD-L1, anti-TIM3), etc.

- Chemotherapy and/or radiation intensification
- Induction chemotherapy
- Immunotherapy, including immune checkpoint blockade (e.g. anti-PD1, anti-TIM3), HPV therapeutic vaccine, or other immunomodulatory approaches
Contributors

P.Y.F.Z, M.J.C, M.S.S, M.I.K, J.W.B, A.C.N designed the study and experiments. P.Y.F.Z, M.J.C, M.S.T, L.D.C, X.L performed the bioinformatic analysis. P.Y.F.Z, M.J.C, M.S.T, L.D.C, X.L, A.C.N reviewed the underlying data. J.W.B performed RNA extraction. M.S.S, S.C, L.L, F.H, R.H.B, C.R.I, K.S, T.P, X.W, F.L, E.P, C.P, S.D.D.S, M.H, J.C.D, P.B, D.M, C.J.H, W.S, J.Y, K.F., A.D, S.E.B, P.P, H.K, D.A.P., P.L, S.D.S, A.M, P.L, E.W, H.Z, A.A, A.C.N provided patients materials and clinical data. P.Y.F.Z, M.S, M.I.K, J.W.B, S.S-C.L, A.A, P.C.B, J.S.M, and A.C.N discussed and data and wrote the text. P.C.B, J.S.M, and A.C.N supervised the study. All authors read and approved the manuscript before submission.

Data sharing statement

Data from the TCGA HNSC cohort included in the current study is available from the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/projects/TCGA-HNSC). Data from the JHU, Washington University at St. Louis, and BD2Decide cohort could be accessed from GEO with accession numbers GSE112026, GSE171898, and GSE163173. Data from the MC1273 and 30ROC trials could be accessed at GSE157517. All other data available via request to corresponding author.

Declaration of interests

PYFZ, JWB, PCB, JSM and ACN have a US patent pending for the UWO3 score. All other authors declare no conflict of interest.

Acknowledgements

ACN was supported by the Wolfe Surgical Research Professorship in the Biology of Head and Neck Cancers Fund. PYFZ is supported by a CIHR Vanier Canada Graduate Scholarship and a PSI Foundation Fellowship. This study was funded by Canadian Institutes of Health Research grants MOP340674 to ACN and PCB, PJT-173496 to JSM and ACN, NIH/NCI award number P50CA016042 to PCB, European Union Horizon 2020 Framework Program Award Number: 689715, and AIRC ID 23573 to LDC. ALA was supported in part by a NIH/NIDCR Developmental Research Program (DRP) Grant from the Yale Head and Neck SPORCE P50 DE030707.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jbiom.2022.104473.

References

1. Meneses FDS, Fernandes GA, Antunes JLF, Villa LL, Toporcov TN. Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: a systematic review of population-based studies. Oral Oncol. 2021;115:105177.
2. Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16:669–683.
3. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
4. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3233–3242.
5. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res. 2010;16(7):2138–2146.
6. Nichols AC, Palma DA, Dhillon SS, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol. 2013;20(4):212–219.
7. Glasserini F, Prokopen SC, MacNeil D, et al. Multimodal analysis of head and neck squamous cell carcinoma stratified by smoking status. JCI Insight. 2019;4(1):e123443.
8. Papillon-Cavanagh S, Lu C, Gayden T, et al. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet. 2017;49(2):180–185.
9. Tfelt H, Winquist E, Nichols AC, et al. Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncol. 2019;89:72–78.
10. Quon H, Vapiliwala N, Forastiere A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol. 2017;35(16):4078–4090.
11. Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873–898.
12. O’Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–550.
13. Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. Eur J Cancer. 2016;68:125–133.
14. Price KB, Nichols AC, Shem C, et al. Novel strategies to effectively de-escalate curative-intent therapy for patients with HPV-associated oropharyngeal cancer: current and future directions. Am Soc Clin Oncol Educ. Book. 2020;49(40):1–13.
15. Palma DA, Prisman E, Berthelet E, et al. Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(6):1–7.
16. Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349–1359.
17. Nichols AC, Theurer J, Prisman E, et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinomas: long-term results of the ORATOR trial. J Clin Oncol. 2022;40(9):OC0210961.
18. Leeman JE, Li JG, Pei X, et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol. 2017;3(11):1487–1494.
19. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.
20. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cetuximab or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60.
21. Adelstein DJ, Ismaila N, Ku JA, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(18):1578–1589.
22. Mehanna H, Rischin D, Wong SJ, et al. De-escalation after DE-ESCALATE and RTOG 1016: a head and neck cancer InterGroup framework for future de-escalation studies. J Clin Oncol. 2020;38(22):2352–2357.
23. Cinela A, Ferris RL, Ceban AM, Seiwert T, Burtress B. Treatment de-intensification for HPV-positive oropharynx cancer: what is currently acceptable? J Clin Oncol. 2021;39(24):2732–2733.
24. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. JAMA Oncol. 2017;3(5):4057–4065.
25. Ma DJ, Price KA, Moore EJ, et al. Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J Clin Oncol. 2019;37(22):1909–1918.
26. Yom SS, Torres-Savedra P, Caudell JJ, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39(9):956–965.
27. Morris LG, Chandramohan R, West L, et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform. JAMA Oncol. 2017;3(2):244–255.
28. Lee N, Schoder H, Beattie B, et al. Strategy of using intratreatment hypoisona imaging to selectively and safely guide radiation dose
de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2016;96(1):9–17.

Zhang Y, Koneva LA, Virani S, et al. Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures. Clin Cancer Res. 2016;22(18):4735–4745.

Prusinkiewicz MA, Gameiro SF, Ghassemi F, et al. Survival-associated metabolic genes in human papillomavirus-positive head and neck cancers. Cancers. 2020;12(1):253.

Gross AM, Orosco RK, Shen JP, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014;46(9):919–943.

Kim HAJ, Shiakhi MH, Lee M, et al. 3p arm loss and survival in head and neck cancer: an analysis of TCGA dataset. Cancers. 2021;13(21):5313.

Shiakhi MH, Barrett JW, Khan ML, et al. Chromosome 3p loss in the progression and prognosis of head and neck cancer. Oral Oncol. 2020;109:104944.

Gebler-Neto FO, Rao X, Guo T, et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019;4(11):e124762.

Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1131–1120.

Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.

Liu X, Liu P, Chernock RD, et al. Clinical validation of a prognostic gene expression cluster-based model in human papillomavirus-positive oropharyngeal carcinoma. JCO Precis Oncol. 2021;5(1):1666–1670.

Riaz N, Sherman E, Pei X, et al. Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. J Natl Cancer Inst. 2021;113(6):742–751.

Morand GB, Diazonecos A, Ibrahim I, et al. Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review. Clin Exp Metastasis. 2022;39(3):407–416.

Upreti D, Zhang ML, Bykova E, Kung SK, Pathak KA. Change in RNAseq aligner. Bioinformatics. 2013;29(1):15–21.

Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2013;29(5):1866–1867.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

Han Y, Yang L, Galvao Neto A, et al. HPVViewer: sensitive and specific genotyping of human papillomavirus in metagenomic DNA. Bioinformatics. 2018;34(12):1986–1995.

Becht E, Girald NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.

Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-ecology. Bioinformatics. 2019;35(14):i436–i445.

Gu Z, Eilers R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847–2849.

Petitprez F, de Reynies A, Keung EZ, et al. B cells are associated with chemotherapy and radiotherapy response in sarcoma. Nature. 2020;577(7791):556–560.

Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39(3):361–379. e16.

Hobbs AJ, Brockton NT, Matthews TW, et al. Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: a population-based study. Head Neck. 2017;39(11):2187–2199.

Bankhead P, Loughrey MB, Fernandez J, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.

Heintz G, Schermer P. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114–119.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7454):557–560.

Pagen F, Milecnik B, Marfot L, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139.

Cillo AR, Kurten CHL, Talib T, et al. Immune landscape of viral- and carcinoma-driven head and neck cancer. Immunity. 2020;52(2):183–199. e9.

Lechner A, Schlösser HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncotarget. 2018;9(3):153529.

Nelson HH, Pawlista M, Michaud DS, et al. Immune response to HPV16 E6 and E7 proteins and patient outcomes in head and neck cancer. JAMA Oncol. 2017;3(2):178–185.

Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2013;29(5):1866–1867.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

Han Y, Yang L, Galvao Neto A, et al. HPVViewer: sensitive and specific genotyping of human papillomavirus in metagenomic DNA. Bioinformatics. 2018;34(12):1986–1995.

Becht E, Girald NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.

Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-ecology. Bioinformatics. 2019;35(14):i436–i445.
75 Eberhardt CS, Kissick HT, Patel MR, et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer. Nature. 2021;597(7875):279–284.

76 Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2021;597(7875):274–278.

77 Curigliano G, Gelderblom H, Mach N, et al. Phase I/Ib clinical trial of sabotolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res. 2021;27(13):3620–3629.

78 Harding JJ, Patnaik A, Moreno V, et al. A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers. J Clin Oncol. 2019;37(8_suppl):12.

79 Ferrarotto R, Bell D, Rubin MI, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8(+) tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin Cancer Res. 2020;26(13):3211–3219.